MTOR and neoplasm: On a direct level, metformin may affect tumor growth by activation of adenosine monophosphate-activated protein kinase (AMPK), its intracellular target for antidiabetic effects, which leads to the regulation of multiple downstream signaling pathways that control cellular proliferation, including inhibition of the mammalian target of rapamycin (mTOR) pathway 7,8.